Sangamo Shares Plummet After Pfizer Exit
Sangamo Therapeutics shares plunged 50% as Pfizer ends collaboration on hemophilia drug, impacting biotech stocks. Discover the implications for investors.
Topic
hemophilia drug
A collection of 3 issues
Sangamo Shares Plummet After Pfizer Ends Collaboration
Sangamo Therapeutics' stock nosedives over 50% as Pfizer halts partnership on hemophilia drug. Discover the implications for Sangamo's future and investor concerns.
Sangamo Stock Falls as Pfizer Ends Hemophilia Collaboration
Sangamo Therapeutics' stock dropped sharply after Pfizer announced it is ending their collaboration on a groundbreaking hemophilia drug. Discover the impact on biotech stocks.